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Sir, An 81 year old lady presented 9 weeks after starting dabrafenib 100mg BD and trametinib 2mg 
OD for metastatic melanoma, complaining of progressive proximal muscle weakness, associated 
with a violaceous macular rash in a V-shaped distribution on the anterior chest, myalgia, facial 
swelling, profound fatigue, and loss of appetite. She was diagnosed with stage III melanoma in 2013, 
and underwent local excision and lymph node resection at the time; however, she relapsed in 2016, 
developing new cutaneous lesions and lungs metastases. Otherwise she had no significant past 
medical history or regular medications. On examination, neck drop was noted, and proximal power 
was reduced to Medical Research Council (MRC) scale 3/5 in the upper limbs and 4/5 in the lower 
limbs. Dabrafenib and trametinib were discontinued, pending further investigations. MRI and CT 
imaging of the head and neck revealed no underlying cause and a paraneoplastic antibody screen 
was negative; however creatinine phosphokinase and CRP were elevated (1350 U/L and 22 mg/L 
respectively), and an EMG showed small, short duration polyphasic units, consistent with the clinical 
diagnosis of dermatomyositis (2017 EULAR/ACR classification criteria: definite idiopathic 
inflammatory myopathy; subgroup dermatomyositis; 99% probability). She had a borderline ANA of 
1:100 but antibodies to Sm, RNP, SSA, SSB and Scl-70 were negative as were myositis specific 
autoantibodies to EJ, Jo-1, Ku, Mi-2, OJ, PL-12, PL-7, PM-Scl100, PM-Scl75 and SRP. There was no 
clinical response to 60mg prednisolone, and although there was a reduction in CK and CRP this was 
not sustained with 40mg prednisolone. Despite continued high dose steroids she went on to develop 
new periungual lesions, nail fold capillary changes, Gottron’s sign over the metacarpophalangeal 
joints, and an unsafe swallow, requiring a PEG insertion. Two doses of IVIg (2g/kg) were 
administered 8 weeks apart, producing an excellent clinical response, with resolution of dysphagia, 
power 5/5 throughout, and normalisation of CRP. Sixteen weeks later she developed a mild 
recurrence of weakness and the macular rash. Further IVIg was administered and then continued at 
8 weekly intervals. She remains off dabrafenib and trametinib and has declined further therapy for 
melanoma.  
Dermatomyositis (DM) belongs to a heterogeneous group of autoinflammatory myopathies 
featuring symmetrical proximal muscle weakness, with or without systemic manifestations. It may 
occur as a paraneoplastic phenomenon, sometimes several months/years before a formal diagnosis 
of malignancy. Nevertheless, the temporal association between the onset of DM and treatment with 
dabrafenib/ trametinib in our case raises the possibility of a drug-associated trigger. Notably, 
interstitial lung disease, myalgia, arthralgia and synovitis, have all been reported as individual side 
effects of dabrafenib and trametinib, and CRP often increases with use of these treatments.  
Dabrafenib and trametinib inhibit two kinases, BRAF and MEK1/2 respectively, within the mitogen-
activated protein kinases/extracellular signal regulated kinases (MAPK/ERK) signalling pathway. They 
are used alone or in combination for melanoma. Overactivity of the MAPK/ERK pathway in 
BRAFv600 mutated melanoma cells drives tumour growth by promoting entry into the cell cycle.  
However activation of the MAPK/ERK pathway is also important for T cell receptor signalling and is 
critical for naive T cell activation with effects on other T cell subsets dependent upon context and 
state of differentiation.[1] Emerging evidence suggests that overactivity of the MAPK/ERK pathway 
in melanoma induces an immunosuppressive environment conducive to propagation of the tumour 
through mechanisms including downregulation of HLA class 1 expression by tumour cells and TGFβ-
dependent induction of T regulatory (Tregs) cells.[2, 3] Experimental evidence suggests that 
MAPK/ERK pathway inhibition may increase the number and activity of CD8+ tumour infiltrating 
lymphocytes, and also more generally reduce Treg function which might impair peripheral 
tolerance.[4, 5] Consequently there is the potential for therapeutic synergy between MAPK/ERK 
pathway  inhibitors and tumour immunity promoting checkpoint blockade.[1] 
Malignancy-associated dermatomyositis may be driven by an immune response to autoantigens on 
tumour cells that crossreact with the same antigens being expressed on regenerating muscle 
fibres.[6] Treg depletion exacerbates disease in animal models,[7] and increased numbers of Tregs in 
muscle were observed following abatacept treatment of refractory inflammatory myositis.[8] 
Therefore it seems plausible that MAPK/ERK pathway inhibition may both enhance tumour 
immunity and also facilitate priming of an autoimmune muscle response, further aggravated by 
possible suppression of Treg function. 
Immune-related adverse events following checkpoint blockade for melanoma and other cancers are 
becoming increasing well-recognised amongst rheumatologists. However the potential for such 
events to follow combination Dabrafenib and Trametinib is not well appreciated. We have reported 
a case of steroid-refractory dermatomyositis with temporal association to Dabrafenib and 
Trametinib therapy. Physicians should be aware of the possibility of autoimmune sequelae arising 
with these drugs. 
Key Message 
Autoimmune events may arise following therapy with MAPK/ERK pathway inhibitors 
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